Related Experiment Video
Updated: Jan 20, 2026

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
Published on: October 26, 2016
Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI): study protocol
Louisa J D van Dijk1,2, Jihan Harki3, Desirée van Noord3,4
1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. l.vandijk@erasmusmc.nl.
Insights
The CoBaGI trial compares covered stents (CS) to bare-metal stents (BMS) for treating chronic mesenteric ischemia (CMI). This study aims to determine which stent type offers better long-term patency and patient outcomes in atherosclerotic CMI.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Gastroenterology
Background:
- Chronic mesenteric ischemia (CMI) stems from reduced blood flow to the intestines, primarily due to atherosclerotic narrowing of mesenteric arteries.
- Revascularization is crucial for managing CMI, preventing severe complications, and improving patient quality of life.
- Endovascular therapy is now the preferred treatment for CMI, with ongoing research into optimal stent technologies.
Purpose of the Study:
- To prospectively evaluate and compare the primary stent patency rates of covered stents (CS) versus bare-metal stents (BMS) in patients with atherosclerotic CMI.
- To assess secondary endpoints including restenosis, symptom recurrence, re-intervention rates, quality of life, and cost-effectiveness.
- To establish CS as a potentially superior option to BMS for treating CMI.
Main Methods:
- The CoBaGI trial is a randomized, controlled, blinded, multicenter superiority trial involving 84 patients.
- Participants are randomized 1:1 to receive either a balloon-expandable BMS or a balloon-expandable CS.
- The primary endpoint is primary stent patency at 24 months, assessed via CT angiography.
Main Results:
- The study is designed to provide definitive data on stent patency at 24 months.
- Secondary analyses will examine patency at 6 and 12 months, alongside clinical outcomes.
- Quality of life and cost-effectiveness will also be analyzed over the 24-month period.
Conclusions:
- The CoBaGI trial is the first randomized controlled trial investigating CS versus BMS for CMI caused by atherosclerotic mesenteric stenosis.
- Results will inform clinical practice regarding the optimal stent choice for CMI treatment.
- The study will also offer insights into the impact of stenting on patient quality of life and its economic implications.
Background:
Chronic mesenteric ischemia (CMI) is the result of insufficient blood supply to the gastrointestinal tract and is caused by atherosclerotic stenosis of one or more mesenteric arteries in > 90% of cases. Revascularization therapy is indicated in patients with a diagnosis of atherosclerotic CMI to relieve symptoms and to prevent acute-on-chronic mesenteric ischemia, which is associated with high morbidity and mortality. Endovascular therapy has rapidly evolved and has replaced surgery as the first choice of treatment in CMI. Bare-metal stents (BMS) are standard care currently, although retrospective studies suggested significantly higher patency rates for covered stents (CS). The Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI) trial is designed to prospectively assess the patency of CS versus BMS in patients with atherosclerotic CMI.
Methods/Design:
The CoBaGI trial is a randomized controlled, parallel-group, patient- and investigator-blinded, superiority, multicenter trial conducted in six centers of the Dutch Mesenteric Ischemia Study group (DMIS). Eighty-four patients with a consensus diagnosis of atherosclerotic CMI are 1:1 randomized to either a balloon-expandable BMS (Palmaz Blue with rapid-exchange delivery system, Cordis Corporation, Bridgewater, NJ, USA) or a balloon-expandable CS (Advanta V12 over-the-wire, Atrium Maquet Getinge Group, Hudson, NH, USA). The primary endpoint is the primary stent-patency rate at 24 months assessed with CT angiography. Secondary endpoints are primary stent patency at 6 and 12 months and secondary patency rates, freedom from restenosis, freedom from symptom recurrence, freedom from re-intervention, quality of life according the EQ-5D-5 L and SF-36 and cost-effectiveness at 6, 12 and 24 months.
Discussion:
The CoBaGI trial is designed to assess the patency rates of CS versus BMS in patients treated for CMI caused by atherosclerotic mesenteric stenosis. Furthermore, the CoBaGI trial should provide insights in the quality of life of these patients before and after stenting and its cost-effectiveness. The CoBaGI trial is the first randomized controlled trial performed in CMI caused by atherosclerotic mesenteric artery stenosis.
Trial Registration:
ClinicalTrials.gov, ID: NCT02428582 . Registered on 29 April 2015.
Related Concept Videos
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Anatomy of the Gastrointestinal System
Here's a detailed walkthrough of this complex system:
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview

